SCHEMBL8427294

SCHEMBL8427294

CCOC(=O)C(Cc1c[nH]c2ccc(Br)cc12)NCl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.53
GABRB1 P18505 1/20 0.53
GABRA3 P34903 1/20 0.53
GABRB2 P47870 1/20 0.53
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
MAPT P10636 3/20 0.51
TP53 P04637 2/20 0.51
LMNA P02545 1/20 0.51
THRB P10828 1/20 0.51
GPR84 Q9NQS5 1/20 0.48
ADAM17 P78536 1/20 0.48
NR4A2 P43354 1/20 0.47
MMP2 P08253 1/20 0.47
MMP3 P08254 1/20 0.47
MEN1 O00255 1/20 0.47
NPBWR1 P48145 1/20 0.47
KMT2A Q03164 1/20 0.47
MCHR1 Q99705 1/20 0.47
ITGB2 P05107 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22122438 0.84 GABRA1 (0.56) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL14116366 0.83 SCN9A (0.64) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL3853949 0.83 SCN9A (0.64) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL5263791 0.83 SCN9A (0.64) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL8427159 0.80 ADAM17 (0.68) ADAM17MMP2
SCHEMBL14116370 0.79 KMT2A (0.59) MTNR1AMTNR1BMAPTTP53GPR84
SCHEMBL31158208 0.78 ITGB2 (0.56) MTNR1AMTNR1BMAPTLMNAGPR84
SCHEMBL3703101 0.78 PKM (0.67) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL30419995 0.78 PKM (0.67) GABRA1GABRB1GABRA3GABRB2MTNR1A
SCHEMBL1197489 0.77 MTNR1A (0.54) GABRA1GABRB1GABRA3GABRB2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 GABRA1 4156/4885GABRB1 3814/4885GABRA3 4271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.